Icosavax Inc

NASDAQ ICVX

Data sourced from

and

Download Data

Icosavax Inc Operating Cash Flow To Current Liabilities for the year ending December 31, 2023

Icosavax Inc Operating Cash Flow To Current Liabilities is NA for the year ending December 31, 2023. The operating cash flow to current liabilities ratio measures the ability of a company's operating cash flow to cover its current liabilities. It is calculated by dividing the operating cash flow by the current liabilities. This ratio indicates the company's short-term liquidity position and its ability to meet its immediate financial obligations using cash generated from its operations. A higher ratio suggests a stronger ability to cover current liabilities with operating cash flow.

Icosavax Inc Operating Cash Flow To Current Liabilities for the year ending December 31, 2022 was -4.47, a -7.22% change year over year.
Icosavax Inc Operating Cash Flow To Current Liabilities for the year ending December 31, 2021 was -4.17, a -71.30% change year over year.
Icosavax Inc Operating Cash Flow To Current Liabilities for the year ending December 31, 2020 was -2.44, a 34.81% change year over year.
Icosavax Inc Operating Cash Flow To Current Liabilities for the year ending December 31, 2019 was -3.74.

NASDAQ: ICVX

Icosavax Inc

CEO	Mr. Adam K. Simpson
IPO Date	July 29, 2021
Location	United States
Headquarters	1616 Eastlake Avenue East, Seattle, WA, United States, 98102
Employees	60
Sector	Healthcare
Industry	Biotechnology

Description

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Key trends